98%
921
2 minutes
20
After spinal cord injury (SCI), secondary injuries including blood cells infiltration followed by the production of inflammatory mediators are led by blood-spinal cord barrier (BSCB) breakdown. Therefore, preventing BSCB damage could alleviate the secondary injury progresses after SCI. Recently, we reported that transient receptor potential melastatin 7 channel (TRPM7) expression is increased in vascular endothelial cells after injury and thereby mediates BSCB disruption. However, the mechanism by which TRPM7 regulates BSCB disruption has not been examined yet. In current research, we show that TRPM7 mediates BSCB disruption via mammalian target of rapamycin (mTOR) pathway after SCI in rats. After contusion injury at T9 level of spinal cord, mTOR pathway was activated in the endothelial cells of blood vessels and TRPM7 was involved in the activation of mTOR pathway. BSCB disruption, MMP-2/9 activation, and blood cell infiltration after injury were alleviated by rapamycin, a mTOR signaling inhibitor. Rapamycin also conserved the level of tight junction proteins, which were decreased after SCI. Furthermore, mTOR pathway regulated the expression and activation of histone H3K27 demethylase JMJD3, known as a key epigenetic regulator mediating BSCB damage after SCI. In addition, rapamycin inhibited JMJD3 expression, the loss of tight junction molecules, and MMP-2/9 expression in bEnd.3, a brain endothelial cell line, after oxygen-glucose deprivation/reoxygenation. Thus, our results suggest that TRPM7 contributes to the BSCB disruption by regulating JMJD3 expression through the mTOR pathway after SCI.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12035-023-03617-z | DOI Listing |
J Ethnopharmacol
August 2025
Beijing Zhendong Guangming Pharmaceutical Research Institute, Beijing, 100085, China. Electronic address:
Ethnopharmacological Relevance: In traditional Chinese medicine (TCM) theory, Compound Kushen Injection (CKI) possesses multiple therapeutic effects, including heat-clearing, detoxification, blood-cooling, dampness-resolving, and pain relief. CKI has been used clinically for 30 years as an adjunctive drug alongside chemotherapy and radiotherapy for cancer treatment. However, the effects of CKI on cancer-induced bone pain (CIBP) and potential mechanisms remain poorly understood.
View Article and Find Full Text PDFFront Pharmacol
July 2025
Department of Rehabilitation Medicine, General Hospital of the Western Theater Command, Chengdu, Sichuan, China.
Background: Valeriana jatamansi Jones, a globally utilized medicinal plant, exhibits favorable pharmacological effects against depression and tumors. Iridoids derived from V. jatamansi (IRFV) promote recovery following spinal cord injury (SCI).
View Article and Find Full Text PDFMater Today Bio
August 2025
Department of Orthopedics (Spine Surgery), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Spinal cord injury (SCI) causes devastating neurological deficits, and cellular senescence critically contributes to the pathogenesis of various diseases. Notably, endothelial cells (ECs) senescence exerts a pivotal effect on the pathogenesis following SCI. In this study, we found that the number of senescent ECs increased by 18.
View Article and Find Full Text PDFFluids Barriers CNS
July 2025
Age-Related and Brain Diseases Research Center, Kyung Hee University, Seoul, 02447, Republic of Korea.
Background: After a spinal cord injury (SCI), disruption of the blood-spinal cord barrier (BSCB) leads to secondary injuries, including inflammatory responses and apoptotic cell death, ultimately causing permanent neurological deficits. Imatinib, a tyrosine kinase inhibitor, has been reported to enhance BSCB integrity and improve functional recovery after SCI. However, the mechanism by which imatinib regulates BSCB integrity remains unclear.
View Article and Find Full Text PDFFluids Barriers CNS
July 2025
Centre de Recherche du CHU de Québec, Université Laval, Axe Neurosciences, Québec, QC, G1V 4G2, Canada.
The complex etiology of neurological disorders is a major challenge to the identification of therapeutic candidates. Tackling brain vascular dysfunction is gaining attention from the scientific community, neurologists and pharmaceutical companies, as a novel disease-modifying strategy. Here, we provide evidence that at least 41% of neurological diseases and related conditions/injuries display a co-pathology of blood-brain and blood-spinal cord barrier alterations and dysfunctions, and we discuss why this figure may represent only a fraction of a larger phenomenon.
View Article and Find Full Text PDF